Primary sinonasal lymphoma: A multi‐institutional experience of clinical presentation, treatment, and outcomes

• DOI: 10.1002/alr.23102
• Publication Date: 2022-11-26T14:30:14Z
• Authors: Jacob G. Eide; Rijul S. Kshirsagar; Jack L. Birkenbeuel; Eric H. Abello; Sara Hobday; Sabrina Herzberg; Beverly Y. Wang; James N. Palmer; Nithin D. Adappa; Edward C. Kuan
• Keywords: Male; Middle Aged; Prognosis; 3. Good health; Lymphoma, Extranodal NK-T-Cell; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Humans; Female; Lymphoma, Large B-Cell, Diffuse; Nasal Cavity; Paranasal Sinus Neoplasms; Aged; Retrospective Studies

Sinonasal lymphoma (SL) is a heterogeneous, underrecognized neoplastic disorder with limited outcomes data. We sought to better define by subtype and treatment at 2 referral centers over the past decades.Demographics, clinicopathologic data, for patients treated SL were queried from January 1, 2000 December 31, 2021 tertiary academic medical centers.Eighty-four included, an average age diagnosis of 63.4 ± 15 years. There 34 females (40.5%). The majority had Eastern Cooperative Oncology Group (ECOG) score <2 (76.2%) most common presenting symptom was facial swelling/pain (26.2%). primary site nasal cavity (36.9%). Diffuse large B-cell (46.4%), followed extranodal NK/T-cell (17.9%). Chemotherapy strategy (n = 59, 70.2%), radiation therapy 35, 41.7%) immunotherapy 24, 28.6%). Disease-specific survival rates 5, 10 years 85.7%, 73.6%, 58.6%, respectively. Eighteen (21.4%) developed recurrence. On multivariate analysis, higher ECOG (p < 0.0001) history head neck 0.048) associated worse survival. Younger greater risk recurrence 0.022) male sex more side effects 0.012).This largest multi-institutional analysis characteristics outcomes. Our work suggests that, although disease control in first 5 reasonable, 10-year remain challenging. Further studies are needed investigate new paradigms stratification.